Study on the efficacy of hyperthermic intraperitoneal chemotherapy in adjuvant treatment of cervical cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050271

Enrollment

Unknown

Registered

2021-08-25

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Experimental group:Hyperthermic intraperitoneal perfusion

Control group:None

Eligibility

Sex/Gender

Female

Age

No minimum to 75 Years

Inclusion criteria

Inclusion criteria: Patients stage diagnosed with cervical cancer at IB1 or above according to the 2018FIGO.

Exclusion criteria

Exclusion criteria: 1.Aged > 75 yeas old; 2.Wide adhesions in abdominal cavity caused by various reasons; 3.Obvious liver and kidney insufficiency; 4.Combined with bone marrow suppression, peripheral blood leukocyte, platelet hypoplasia; 5.Serious cardiovascular system lesions; 6.Infectious diseases, especially severe abdominal infection; 7.Bleeding tendency or coagulation dysfunction; 8.Unstable vital signs; 9.Cachexia.

Design outcomes

Primary

Measure	Time frame
relapse free survival;	—

Countries

China

Contacts

Public ContactHuang Liqiog

Chengdu Women's and Children's Central Hospital

591565534@qq.com+86 18180799658

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026